Brokers Offer Predictions for SCYNEXIS Q1 Earnings

SCYNEXIS, Inc. (NASDAQ:SCYX) – Analysts at Brookline Capital Acquisition issued their Q1 2026 earnings per share estimates for shares of SCYNEXIS in a research note issued to investors on Monday, March 9th. Brookline Capital Acquisition analyst K. Dolliver expects that the company will post earnings per share of ($0.10) for the quarter. Brookline Capital Acquisition currently has a “Buy” rating on the stock. Brookline Capital Acquisition also issued estimates for SCYNEXIS’s Q2 2026 earnings at ($0.10) EPS, Q3 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.05) EPS and FY2030 earnings at $0.46 EPS.

Several other equities research analysts also recently commented on SCYX. Weiss Ratings restated a “sell (d-)” rating on shares of SCYNEXIS in a research report on Monday, December 29th. Wall Street Zen upgraded shares of SCYNEXIS from a “hold” rating to a “strong-buy” rating in a research report on Saturday, March 7th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $3.00.

SCYNEXIS Price Performance

SCYNEXIS stock opened at $0.89 on Wednesday. The firm’s 50 day simple moving average is $0.74 and its 200-day simple moving average is $0.75. The company has a market cap of $39.84 million, a P/E ratio of -5.25 and a beta of 1.33. SCYNEXIS has a fifty-two week low of $0.57 and a fifty-two week high of $1.31.

SCYNEXIS (NASDAQ:SCYX) last posted its quarterly earnings data on Wednesday, March 4th. The company reported $0.25 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.04). SCYNEXIS had a negative return on equity of 25.52% and a negative net margin of 41.79%.The company had revenue of $17.20 million for the quarter, compared to analyst estimates of $8.10 million.

Hedge Funds Weigh In On SCYNEXIS

Several institutional investors and hedge funds have recently modified their holdings of SCYX. Jane Street Group LLC bought a new position in shares of SCYNEXIS in the 2nd quarter valued at approximately $27,000. Sequoia Financial Advisors LLC acquired a new stake in shares of SCYNEXIS during the 3rd quarter valued at about $41,000. GSA Capital Partners LLP lifted its position in shares of SCYNEXIS by 95.2% during the 3rd quarter. GSA Capital Partners LLP now owns 104,423 shares of the company’s stock worth $80,000 after buying an additional 50,916 shares during the period. Bridgeway Capital Management LLC lifted its holdings in shares of SCYNEXIS by 4.2% during the second quarter. Bridgeway Capital Management LLC now owns 368,180 shares of the company’s stock valued at $248,000 after acquiring an additional 14,689 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in SCYNEXIS by 7.1% during the 4th quarter. Geode Capital Management LLC now owns 449,223 shares of the company’s stock valued at $284,000 after purchasing an additional 29,775 shares during the last quarter. 54.37% of the stock is currently owned by hedge funds and other institutional investors.

SCYNEXIS Company Profile

SCYNEXIS, Inc is a late‐stage biopharmaceutical company focused on developing and commercializing novel anti‐infective therapies. Headquartered in Jersey City, New Jersey, the company’s primary research and development efforts center on combating invasive and chronic fungal infections, an area of high unmet medical need. SCYNEXIS’s scientific platform is built around its proprietary triterpenoid class of antifungals, which are designed to address resistance and safety limitations associated with existing treatments.

The company’s lead product candidate, ibrexafungerp, represents the first oral glucan synthase inhibitor to reach clinical development.